Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470140 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Wugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05470140: Completed Phase 1 study, sponsored by Wugen.
NCT05470140 is a Phase 1 study that has completed, run by Wugen. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05470140, a Phase 1 study, has completed, sponsored by Wugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.
Primary Outcome
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of consent until End of Study (EOS) visit.
Interventions
- BIOLOGICAL WU-NK-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
What the finished NCT05470140 record still lists
NCT05470140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which WU-NK-101 is the first listed.
NCT05470140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05470140 about?
NCT05470140 is a clinical study titled "A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)". This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.
What is the current status of trial NCT05470140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-07-01. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT05470140?
The interventions under investigation include: WU-NK-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05470140?
This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05470140's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI